New and experimental HIV treatments: latest news

New and experimental HIV treatments features

New and experimental HIV treatments in your own words

New and experimental HIV treatments news from aidsmap

More news

New and experimental HIV treatments news selected from other sources

  • Merck Receives CHMP Positive Opinion Recommending Approval of ISENTRESS® (raltegravir) 600 mg in the European Union

    In adults and pediatric patients (weighing at least 40 kg), the recommended dosage is 1,200 mg (two 600 mg tablets) once daily for treatment-naïve patients or patients who are virologically suppressed on an initial regimen of ISENTRESS 400 mg twice daily.

    22 May 2017 | Merck press release
  • CHMP recommends for approval generic version of Atripla

    At its May meeting, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended for approval a generic version of Atripla – Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva (efavirenz/emtricitabine/tenofovir disoproxil) for the treatment of HIV infection.

    22 May 2017 | EATG
  • Gilead's last chronic HIV drug — and what it plans to do now

    Gilead Sciences Inc. — whose HIV-fighting drugs have helped to nearly triple the lives of people with the HIV virus and reduce the number of pills patients pop from 25 to one — expects this fall to ask government regulators to approve its final chronic HIV treatment.

    11 May 2017 | San Francisco Business Times
  • Orphan Drug Designation for CytoDyn's PRO 140 Declined by the FDA

    Cytodyn has announced that its application for Orphan Drug Designation (ODD) for PRO 140 was not granted by the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) because PRO 140 appears to have the potential to treat more than just the subset of multi-drug resistant HIV patients for which the designation was requested.

    18 April 2017 | Cytodyn press release
  • New antibody therapy “profoundly” successful at reducing inflammation from HIV

    In a very small study of people living with HIV, a one-time antibody treatment significantly reduced the type of inflammation that can lead to heart attacks and other cardiovascular problems.

    09 March 2017 | BETA blog
  • Clinical Commissioning Policy: Tenofovir Alafenamide for treatment of HIV 1 in adults and adolescents

    TAF containing products can be made available to patients who have defined renal or bone problems or who have medical reasons why they cannot take other HIV drugs.

    06 March 2017 | NHS England
  • New nano approach could cut dose of leading HIV treatment in half

    Successful results of a University of Liverpool-led trial that utilised nanotechnology to improve drug therapies for HIV patients has been presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, a leading annual conference of HIV research, clinical practice and progress.

    21 February 2017 | University of Liverpool press release
  • Merck's lead HIV play hits the mark in first phase 3 challenge

    Merck has taken a big step toward getting its lead HIV candidate doravirine to market, setting up a showdown with Johnson & Johnson's big-selling Prezista.

    19 February 2017 | FierceBiotech
  • URMC drug extends effectiveness of HIV therapy

    A drug developed at the University of Rochester Medical Center extends the effectiveness of multiple HIV therapies by unleashing a cell's own protective machinery on the virus. The finding, published today in the Journal of Clinical Investigation, is an important step towards the creation of long-acting HIV drugs that could be administered once or twice per year, in contrast to current HIV treatments that must be taken daily.

    31 January 2017 | EurekAlert (press release)
  • SA can save billions with new HIV drug combination

    The ADVANCE study will evaluate an HIV treatment regimen including two newer and cheaper drugs: dolutegravir (DTG) and tenofovir alafenamide (TAF).

    17 January 2017 | Health24
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.